SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DMTC or DIAMOND The Cat Coin is a viral meme coin on Solana Blockchain, Based in Thailand and Global and Based on a true story about my lovely cat(DIAMOND) and made by love, I just want my cat to be immortal in this whole world until I die that's a first idea of this project start. We're start from $2,000 Market cap and hit All time high at $10.9 million, please come to check our project and let's DMTC get list on Coingecko to let's everyone in this whole world know DMTC.

DIAMOND The Cat Coin

DIAMOND The Cat Coin ($DMTC.X) is gaining attention as community members highlight its potential for a breakout, noting accumulation and strong chart signals. The coin is being touted as the next hidden gem, with many suggesting it's ready for a significant upward move. Conversations revolve around the idea that early buyers will be rewarded as $DMTC.X prepares for a "moon shot."

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community celebrates new all-time highs and anticipates upcoming listings. Active community members highlight the project's long-term vision and real-world utilities within the Solana ecosystem. The community is rallying together to push for even greater milestones, with a focus on strong community backing.

Pump.fun

PUMP.X is trending as it rebounds from a dip, with the community expressing excitement about its potential for significant gains, some comparing it to the early days of Dogecoin. Discussions revolve around its role as a platform token within the Solana meme coin ecosystem, with bullish sentiment fueled by updates and community control over creator rewards. Traders are closely watching key resistance levels, anticipating a breakout and a move towards higher price targets.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to its recent merger with Strive Enterprises, creating a publicly traded Bitcoin treasury company and sparking significant community discussion around a potential short squeeze. The merger provides substantial funding for Bitcoin acquisitions, with the community closely monitoring borrow rates and potential catalysts for a price surge. Some traders are looking for quick gains while other members are excited for long term growth.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as community members celebrate its performance and the project's commitment to charitable donations. Built on Solana, UpDog is gaining attention for its longevity and growing community, with holders actively promoting its potential and unique meme-based identity.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending with mixed sentiment, as users discuss the approaching end of the KYC grace period and speculate on its impact to tokenomics. While some community members express optimism about future utility and scarcity, others voice concerns around unverified balances and the lack of major exchange listings. Discussions also involve mining rates, price predictions, and the potential for AI integration within the Pi ecosystem.

ZoraAI agents are designed to take the complexity out of everyday tasks, leaving you with more time and energy to focus on what matters most. With their powerful automation and adaptability, your life and work will become more efficient and effortless. With ZoraAI, you’re in control. The customizable agents feature lets you mix and match your favorite tools and capabilities from different agents to build one that’s perfectly tailored to your needs. Whether you want a multitasking powerhouse or a focused specialist, your personalized agent is designed to work exactly how you want it to—no coding required.

Zoracles

Zoracles ($ZORA.X) is trending due to recent price volatility, leading to active discussions about potential breakouts and resistance levels within the community. Some traders believe it's primed for a significant move, drawing comparisons to similar tokens, while others express concerns about its ability to sustain gains. The community speculates on the impact of potential FED rate cuts and overall market sentiment on altcoins.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis (AVNT.X) is trending as community members discuss its potential for significant gains, drawing comparisons to other successful tokens. Conversations highlight its strong backing and recent listing, with some suggesting it could reach $1 soon. The community is actively watching for breakout signals and discussing entry points.

“$PIXIE is the original Bitcoin Fairy mascot brought to life on Solana. First hidden on Bitcoin.org since 2009, Pixie represents one of the earliest and most authentic memes in crypto history. This project is fully community-driven and built with transparency, with supply locks, open communication, and a clear roadmap. The goal is to grow $PIXIE into the billions by combining strong branding, continuous marketing, and community power — not just as a meme, but as a long-term movement.”

Bitcoin's Fairy Mascot

PIXIE.X is trending as social media buzz positions it as a potential mascot for Bitcoin. Community members are actively discussing its potential role and integration within the broader cryptocurrency ecosystem.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the NFL season approaches, with analysts predicting a record-breaking betting handle. Community members are discussing potential catalysts, including positive earnings reports and expansion into new markets, alongside concerns about competition from prediction markets. Some are frustrated with the stock's performance, while others remain optimistic about its long-term potential in the growing sports betting industry.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly (LLY) and Novo Nordisk (NVO) are reportedly expected to launch oral obesity pills by next year once they get regulatory approval in the U.S.According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. Daily pills would likely bring GLP-1s to more people, the report stated.&nbsp;The report noted that the primary aim of the study is to assess the effectiveness of the pills in lowering blood sugar levels in individuals with Type 2 diabetes, while also monitoring their impact on weight loss.“We wouldn’t have undertaken this head-to-head phase three randomized control trial unless we had a lot of confidence that orforglipron would fare well in comparison to oral semaglutide,” Skovronsky told CNBC.Retail sentiment on <a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> remained unchanged in the ‘neutral’ territory, with message volumes at ‘low’ levels, according to Stocktwits data.The report said that Skovronsky noted the results across trials, which did not directly compare the two drugs, should not be made, given Novo’s pill appears more effective with fewer discontinuations.&nbsp;Meanwhile, Novo’s Chief Scientific Officer, Martin Holst Lange, told CNBC in another interview that the data speaks for itself.Retail sentiment on <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained in the ‘bearish’ territory, with chatter at ‘low’ levels, according to data from Stocktwits.The report explained that Novo’s upcoming obesity pill is a tablet form of its weekly injection, Wegovy. In contrast, Lilly’s pill, Orforglipron, is a completely new drug and different from its injectable treatment, Zepbound. According to Skovronsky, Zepbound remains the benchmark for effectiveness, helping patients lose over 20% of their body weight.The CNBC report noted that neither Novo’s pill nor Lilly’s oral drug is as effective as Zepbound. It added that Orforglipron&nbsp;has achieved around 12% weight loss at its highest dose, while oral Semaglutide&nbsp;has reached about 17%, prompting uncertainty over how many patients will choose a pill if it delivers less weight loss than injectable options.Skovronsky told CNBC that pills could eventually become the primary way that obesity would be treated, and that oral drugs could have a larger market share than shots.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rh-stock-sees-slew-price-target-cuts-from-wall-street-as-trump-tariffs-bite/chw8MrGRdDN">RH Stock Sees Slew Of Downgrades, Price Target Cuts From Wall Street As Trump Tariffs Bite</a>

While Lilly’s broader portfolio spans diabetes, cancer, and neuroscience treatments, investors remain largely focused on Mounjaro and Zepbound. 

Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company expects trial results within months from a direct comparison between its oral drug Orforglipron and Novo Nordisk’s Semaglutide.

Equity

According to a CNBC report, which cited an interview with Lilly’s Chief Scientific Officer, Dan Skovronsky, the company anticipates receiving results in the next few months from a head-to-head trial between its oral drug, Orforglipron, and Novo Nordisk’s oral Semaglutide. 

AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock

ABBV secures Rinvoq's market lead until 2037, boosting shares as strong sales and new indications fuel long-term growth prospects.

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer

Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.

Is NVO's Major Restructuring Plan an Indication to Sell the Stock?

Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.

Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

The Institute for Clinical and Economic Review (ICER) determined on Tuesday that Novo Nordisk (NVO) and Eli Lilly and Co.’s (LLY) weight loss drugs are cost-effective, a judgment that is a “win” for the two companies, according to Bank of America.The ICER <a target="_blank" rel="noopener noreferrer nofollow" href="https://icer.org/wp-content/uploads/2025/09/ICER_Obesity_Draft-Report_For-Publication_090925.pdf">released</a> a draft report assessing the comparative clinical effectiveness and value of Novo’s Semaglutide and Lilly’s Tirzepatide weight loss drugs for obesity management on Tuesday and judged oral Semaglutide, injectable Semaglutide, and injectable Tirzepatide as cost-effective. The firm estimated net prices of $6,830 for Semaglutide and $7,973 for Tirzepatide.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY stock</a> stayed within ‘bearish’ territory over the past 24 hours while message volume rose from ‘extremely low’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_1_58_02_PM_png_608eca0732.webp" alt="LLY's Sentiment Meter and Message Volume as of 1:58 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>LLY's Sentiment Meter and Message Volume as of 1:58 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment on <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed in ‘bearish’ territory, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:574/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_1_59_11_PM_png_ce8ef38022.webp" alt="NVO's Sentiment Meter and Message Volume as of 1:59 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="574" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 1:59 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure> ICER, however, flagged certain affordability concerns. ‘We estimate that fewer than 1% of eligible patients could be treated at current and assumed net prices….This raises serious concerns about affordability,” it said.The firm also noted that it has evidence demonstrating greater weight loss with Lilly’s Tirzepatide than Novo’s Semaglutide. However, in the absence of more details regarding the cardiovascular effects of the two drugs, it considers treatment with Tirzepatide compared with Semaglutide to be “promising but inconclusive.”The firm also noted that oral Semaglutide resulted in slightly lower amounts of weight loss compared to injectable Semaglutide, but provided the uncertainty regarding cardiovascular benefits, judged oral Semaglutide to be “comparable or worse” than injectable Semaglutide.ICER will hold a public meeting on the draft report on November 13, after which it will issue a final report. The findings within the firm’s draft report should not be interpreted as its conclusions, the firm said.BofA views the analysis as "an important and necessary step" toward securing better coverage from employers and payers for GLP-1 category weight loss drugs, according to TheFly. The analyst kept a ‘Buy’ rating and $900 price target on Eli Lilly shares, representing an upside of nearly 22% from Lilly’s closing price on Monday.While LLY stock is down by 3% this year, NVO stock is down 37%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/hedge-fund-reportedly-prepares-to-launch-board-fight-at-orasure-technologies/chwKOS6Rdtq">Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A very overweight woman with swollen feet stands on a scale that reads 145.1 kilograms. Overweight and obesity are increasing at a rapid pace worldwide. Photo: Pia Bayer/dpa (Photo by Pia Bayer/picture alliance via Getty Images)

Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’

BofA views the analysis as "an important and necessary step" toward securing better coverage from employers and payers for GLP-1 category weight loss drugs, according to TheFly.

LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal

Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.

Will LLY's Oncology Portfolio Provide Key Diversification Benefits?

Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.

Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?

MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

LLY
Lilly(Eli) & Co

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LLY News

LLY Lilly(Eli) & Co